Valerio Therapeutics completes acquisition of Etherna Immunotherapies
Bitget2026/10/12 06:19- Valerio Therapeutics completed the acquisition of Etherna Immunotherapies, taking 100% of its share capital and voting rights.
- Deal valued Etherna at an enterprise value of EUR 30 million, funded through cash consideration and share consideration.
- Cash portion was funded via issuance of 68,220,333 new ordinary shares at EUR 0.59 each, raising about EUR 40.25 million.
- Transaction expands an integrated RNA platform spanning nucleic acid chemistry, lipid nanoparticle delivery, targeted moiety engineering, manufacturing.
- Post-transaction share capital totals 587,615,993 shares, with Artal International holding 42.6%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Simwon America (SWA.US) applies for Nasdaq IPO, plans to raise up to $50 million
Simwon America, a manufacturer of structural components for electric vehicles, filed for an IPO with the U.S. Securities and Exchange Commission (SEC) last Friday, aiming to raise up to $50 million. The company is a spinoff of Korea’s MS Autotech.
Sui Foundation Invests $30M in DATA Network as It Moves to Sui post-167040 post-167040 post-167040
Equities: Stable oil and yields support stock gains - Danske Bank
Dental caries treatment provider vVardis (VVVV.US) submits US IPO application, expected to raise 200 million USD
vVardis Holding filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) last Friday. The company focuses on self-developed non-invasive restorative therapies for the early treatment of dental caries. The IPO is expected to raise 200 millions USD.
Crypto prices
More
